Clinical trial NCT00677092 - References

Nephrogenic Systemic Fibrosis — Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

Citation(s)

•   Kay J, Bazari H, Avery LL, Koreishi AF
  Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008 Feb 21;358(8):827-38. doi: 10.1056/NEJMcpc0708697.
•   Kay J, High WA
  Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug;58(8):2543-8. doi: 10.1002/art.23696.
•   Kay J
  Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb;75(2):112, 114, 117. Review.
•   Kay J
  Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii66-9. doi: 10.1136/ard.2008.102475. Review.
•   Todd DJ, Kagan A, Chibnik LB, Kay J
  Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct;56(10):3433-41.

An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis

Details for clinical trial NCT00677092